scholarly journals Complex immune correlates of protection in HIV-1 vaccine efficacy trials

2017 ◽  
Vol 275 (1) ◽  
pp. 245-261 ◽  
Author(s):  
Georgia D. Tomaras ◽  
Stanley A. Plotkin
Keyword(s):  
Vaccine Efficacy ◽  
Correlates Of Protection ◽  
Immune Correlates ◽  
Efficacy Trials ◽  
Hiv 1

scholarly journals Accelerating HIV-1 Vaccine Efficacy Trials

Cell ◽  
2014 ◽  
Vol 159 (5) ◽  
pp. 969-972 ◽  
Author(s):  
Dan H. Barouch ◽  
Nelson L. Michael
Keyword(s):  
Vaccine Efficacy ◽  
Efficacy Trials ◽  
Hiv 1

scholarly journals Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

2016 ◽  
Vol 23 (3) ◽  
pp. 228-235 ◽  
Author(s):  
Andrew J. Dunning ◽  
Carlos A. DiazGranados ◽  
Timothy Voloshen ◽  
Branda Hu ◽  
Victoria A. Landolfi ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Vaccine Efficacy ◽  
Standard Dose ◽  
The Elderly ◽  
High Dose ◽  
Efficacy Trial ◽  
Correlates Of Protection ◽  
Immune Correlates ◽  
Immunologic Assays ◽  
Dose Vaccine

ABSTRACTAlthough a number of studies have investigated and quantified immune correlates of protection against influenza in adults and children, data on immune protection in the elderly are sparse. A recent vaccine efficacy trial comparing standard-dose with high-dose inactivated influenza vaccine in persons 65 years of age and older provided the opportunity to examine the relationship between values of three immunologic assays and protection against community-acquired A/H3N2 influenza illness. The high-dose vaccine induced significantly higher antibody titers than the standard-dose vaccine for all assays. For the hemagglutination inhibition assay, a titer of 40 was found to correspond with 50% protection when the assay virus was antigenically well matched to the circulating virus—the same titer as is generally recognized for 50% protection in younger adults. A dramatically higher titer was required for 50% protection when the assay virus was a poor match to the circulating virus. With the well-matched virus, some protection was seen at the lowest titers; with the poorly matched virus, high levels of protection were not achieved even at the highest titers. Strong associations were also seen between virus neutralization test titers and protection, but reliable estimates for 50% protection were not obtained. An association was seen between titers of an enzyme-linked lectin assay for antineuraminidase N2 antibodies and protection; in particular, the proportion of treatment effect explained by assay titer in models that included both this assay and one of the other assays was consistently higher than in models that included either assay alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01427309.)

Trends in HIV-1 Incidence in a Cohort of Prostitutes in Kenya: Implications for HIV-1 Vaccine Efficacy Trials

2000 ◽  
Vol 24 (5) ◽  
pp. 458-464 ◽  
Author(s):  
Jared M. Baeten ◽  
Barbra A. Richardson ◽  
Harold L. Martin ◽  
Patrick M. Nyange ◽  
Ludo Lavreys ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Efficacy Trials ◽  
Hiv 1

scholarly journals A Zigzag but Upward Way to Develop an HIV-1 Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 511
Author(s):  
Ziyu Wen ◽  
Caijun Sun
Keyword(s):  
Viral Vectors ◽  
Protective Efficacy ◽  
Effective Vaccine ◽  
Immunological Parameters ◽  
Recombinant Viruses ◽  
Correlates Of Protection ◽  
Immune Correlates ◽  
Immunodeficiency Virus ◽  
Hiv 1

After decades of its epidemic, the human immunodeficiency virus type 1 (HIV-1) is still rampant worldwide. An effective vaccine is considered to be the ultimate strategy to control and prevent the spread of HIV-1. To date, hundreds of clinical trials for HIV-1 vaccines have been tested. However, there is no HIV-1 vaccine available yet, mostly because the immune correlates of protection against HIV-1 infection are not fully understood. Currently, a variety of recombinant viruses-vectored HIV-1 vaccine candidates are extensively studied as promising strategies to elicit the appropriate immune response to control HIV-1 infection. In this review, we summarize the current findings on the immunological parameters to predict the protective efficacy of HIV-1 vaccines, and highlight the latest advances on HIV-1 vaccines based on viral vectors.

scholarly journals Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa

PLoS ONE ◽  
2016 ◽  
Vol 11 (7) ◽  
pp. e0157391 ◽  
Author(s):  
Carlo Zambonelli ◽  
Antu K. Dey ◽  
Susan Hilt ◽  
Samuel Stephenson ◽  
Eden P. Go ◽  
...  
Keyword(s):  
Southern Africa ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Proof Of Concept ◽  
Subtype C ◽  
Efficacy Trials ◽  
Gp120 Protein ◽  
Protein Boost ◽  
Hiv 1

scholarly journals Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials

2012 ◽  
Vol 205 (12) ◽  
pp. 1806-1810 ◽  
Author(s):  
Kathryn E. Stephenson ◽  
John Hural ◽  
Susan P. Buchbinder ◽  
Faruk Sinangil ◽  
Dan H. Barouch
Keyword(s):  
Vaccine Efficacy ◽  
Efficacy Trials ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document